Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 10,535 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Not applicable Interventional Results available

Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components

NCT05318183
View directory record Official record
Conditions
PreDiabetes, Dysbiosis, Endotoxemia, Inflammation
Interventions
Whole Wheat Bread, White Bread (control)
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 1 Interventional

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

NCT01695941
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Alisertib, Bortezomib, Laboratory Biomarker Analysis, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
4
States / cities
New York, New York • The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

NCT03520491
View directory record Official record
Conditions
Bladder Cancer
Interventions
Nivolumab, Ipilimumab, Radical cystectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study

NCT04837118
View directory record Official record
Conditions
Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Obesity and Pediatric Multiple Sclerosis

NCT04593082
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 20 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting No phase listed Observational

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

NCT06980623
View directory record Official record
Conditions
Type 2 Diabetes, Heart Failure
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
26,000 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Multivitamin and Mineral Supplementation and Healthy Aging

NCT07642869
View directory record Official record
Conditions
Healthy Aging, Multivitamin and Mineral Supplementation
Interventions
MVM Core Blend, MVM Gold Blend, Placebo
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting No phase listed Observational

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism

NCT07189988
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
psilocybin
Other
Lead sponsor
Healing Advocacy Fund
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

NCT06414603
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
The Prospera™ Test
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Feasibility and Effectiveness of Therapy Together

NCT07225673
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Therapy Together - 4 hour group, Therapy Together - 1 hour group
Behavioral
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
3 Months to 59 Months
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Telehealth-Enhanced Assessment and Management

NCT06247254
View directory record Official record
Conditions
Blood Pressure
Interventions
Intensive Clinic Management, Intensive Tailored Telehealth Management
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Obstetric Complications With Dietary Intervention

NCT06320054
View directory record Official record
Conditions
Gestational Diabetes, Gestational Hypertension, High Risk Pregnancy, Preeclampsia
Interventions
Maternal Health Management Program
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

NCT04675294
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
evorpacept, pembrolizumab
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Irvine, California • La Jolla, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

NCT05972629
View directory record Official record
Conditions
Phenylketonuria
Interventions
SAR444836
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 1 Interventional

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579
View directory record Official record
Conditions
Multiple Myeloma
Interventions
P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
23
States / cities
Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting No phase listed Observational

ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study

NCT00410241
View directory record Official record
Conditions
Healthy Volunteers, Atherosclerotic Heart Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Years to 95 Years
Enrollment
1,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

NCT06153641
View directory record Official record
Conditions
Liver Transplant Rejection, Liver Transplant Failure and Rejection
Interventions
N/A-Observational Study
Other
Lead sponsor
St. Louis University
Other
Eligibility
1 Year and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 1 Interventional Results available

Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness

NCT03814356
View directory record Official record
Conditions
Brain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered, Anoxic Brain Injury
Interventions
Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 3 Interventional

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

NCT05644561
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional Results available

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

NCT04189783
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
Liposomal Bupivacaine, Quadratus Lumborum Block, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

NCT04233866
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride, Leucovorin, Leucovorin Calcium, Liposomal Irinotecan, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
70 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
760
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 501 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Avoid and Resist Strategies for Weight Management

NCT05143931
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Home food environment and grocery delivery (AVOID), Inhibitory control training (RESIST), WW
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
14 Years and older
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053
View directory record Official record
Conditions
Asthma
Interventions
GSK5784283, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
53
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease

NCT07522645
View directory record Official record
Conditions
ASCVD, Diabetes
Interventions
SMS (Initial Outreach), Secure Portal Message (Initial Outreach), Non-secure Email (Initial Outreach), SMS (Follow-up for Non-responders), Secure Portal Message (Follow-up for Non-responders), Non-secure Email (Follow-up for Non-responders)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pleasant Hill, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 14, 2026, 10:57 PM EST